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Purpose: To analyze the baseline clinical factors and medication treatment strategy used in cases with medication treatment 
failure of benign prostatic hyperplasia (BPH).
Methods: From January 2006 to December 2009, 677 BPH patients with at least 3 months of treatment with medication were 
enrolled. We analyzed clinical factors by medication failure (n=161) versus maintenance (n=516), by prostate size (less than 30 g, 
n=231; 30 to 50 g, n=244; greater than 50 g, n=202), and by prostate-specific antigen (PSA) levels (less than 1.4 ng/mL, 
n=324; more than 1.4 ng/mL, n=353).
Results: Age, combination medication rate, PSA, and prostate volume were statistically different between the medication treat-
ment failure and maintenance groups. By prostate size, the PSA and medication failure rates were relatively higher and the med-
ication period was shorter in patients with a prostate size of more than 30 g. The combination medication rate was higher in pa-
tients with a prostate size of more than 50 g. The medication failure rate and prostate volume were higher in patients with a PSA 
level of more than 1.4 ng/mL. However, the combination treatment rate was not significantly different in patients with a PSA level 
lower than 1.4 ng/mL. Suggestive cutoffs for combination medication are a prostate volume of 34 g and PSA level of 1.9 ng/mL.
Conclusions: The clinical factors associated with medication failure were age, treatment type, and prostate volume. Combination 
therapy should be considered more in Korea in patients with a PSA level higher than 1.4 ng/mL and a prostate volume of between 
30 and 50 g to prevent medication failure.
Keywords: Benign prostatic hyperplasia; Combination medication; Medication failure
Corresponding author:  Jeong Gu Lee 
Department of Urology, Korea University Anam Hospital, Korea University 
School of Medicine, Anam-dong 5-ga, Seongbuk-gu, Seoul 136-705, Korea 
Tel: +82-02-920-5683 / Fax: +82-02-928-7864 / E-mal: jeongkl@kumc.or.kr
Submitted:  December 10, 2010 / Accepted after revision:  December 23, 2010
INTRODUCTION 
Over the past decade, there has been a significant decline in the 
frequency of surgery to manage the symptoms associated with 
benign prostatic hyperplasia (BPH). Medication therapy is now 
the most common treatment option used in clinical practice. 
Knowledge of the progressive nature and the risk of BPH pro-
gression are increasing. Our understanding of the pharmaco-
logical effects of BPH continues to evolve, so there are an in-
creasing number of therapeutic choices for individual patients 
with BPH. Currently, most patients who visit a urologist for 
lower urinary tract symptoms (LUTS) are given empirical treat-
ment with an alpha-adrenergic blocker (α-blocker) either with 
or without a 5-alpha reductase inhibitor (5-ARI). It is impor-
tant for clinicians to determine which patients are at increased 
risk for disease progression in order to provide optimal therapy 
and a treatment approach consistent with patient preferences. 
  Uncontrolled disease progression is characterized by aggra-
vation of symptoms, deterioration of the urinary flow rate, in-
crease in prostate volume, and the need for BPH-related surgery. 
Numerous factors have been shown to be linked to the risk of 
BPH progression [1]. Although treatment with α-blockers and 
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5-ARIs usually results in improvement in symptoms and uro-
flowmetric parameters, the rate of medication failure and the 
probability of a patient requiring surgery remain unknown. The 
goal of this study was to determine the baseline factors associ-
ated with medication failure in patients with symptomatic BPH 
and the treatment strategy used for BPH management.
MATERIALS AND METHODS
From January 2006 to December 2009, we reviewed the medi-
cal records of all male patients presenting with LUTS under the 
approval of a relevant ethics committee. After routine initial 
baseline studies, 677 patients who were diagnosed with BPH 
and who had received at least 3 months of medication were en-
rolled. Patients were excluded from the study if they had blad-
der surgery, urethral surgery, previous prostate surgery, or a 
prostate malignancy. Patients with strictly controlled diabetes 
or hepatic, renal, or cardiovascular dysfunction without com-
plications were included. All patients were prescribed α-blockers 
and/or 5-ARI. The rates of patient were checked into alpha-
blocker monotheraphy and α-blockers plus 5-ARI combination 
medication. The dosage of the α-blocker was determined by ti-
tration at biweekly intervals over 8 weeks to reach maximum 
efficacy. We initially determined the International Prostate 
Symptom Score (IPSS), maximum uroflow rate (Qmax), pros-
tate volume, postvoid residual urine volume (PVR), blood urea 
nitrogen (BUN), creatinine, and PSA levels as the clinical base-
line factors. Each eligible patient was asked to fill out the IPSS 
questionnaire. The maximum urinary flow rate (mL/sec) was 
measured by uroflowmetry. PVR (mL) was measured by use of 
diagnostic ultrasound. The prostate volume (mL) was measured 
and an integrated volumetric program automatically calculated 
the volume by using the following formula: volume 1/4 width× 
length×height×0.5236 [2]. 
  During the follow-up, the medication failure group was de-
fined as patients in whom surgical treatment was performed, 
especially transurethral surgery in patients who declined further 
medical treatment or patients who had spontaneous acute uri-
nary retention (AUR) and required suprapubic or urethral cath-
eterization. The medication maintenance group included pa-
tients who did not require surgical or AUR treatment and the 
ration of medication maintenance or failure were also analyzed. 
In addition, comparison was made across tertile distributions 
of prostate size defined by weight; the following categories were 
evaluated: less than 30 g, 30 to 50 g, and 50 g or greater. Further-
more, comparison of stratified by PSA levels was performed with 
the cutoff of 1.4 ng/mL. All the variables: uroflometric parame-
ters and symptom scores were included in the analysis by pros-
tate volume and PSA.  
  Data entry and statistical analyses were performed with SPSS 
ver. 12.0 (SPSS Inc., Chicago, IL, USA). Baseline values of the 
clinical factors were analyzed by using the independent t-test, 
Pearson chi-square test, ANOVA test, and Kaplan Meier plot 
graphically. A logistic regression analysis was used to determine 
the baseline clinical factors, and receiver operating characteris-
tic (ROC) curves were used to determine the cutoff values for 
prostate volume and PSA associated with medication failure.
RESULTS
Among 677 patients, 516 patients maintained medical treatment 
over 3 months and 161 patients were classified as the medication 
failure group. Of the patients in the medication failure group, 
92 patients (60.8%) underwent BPH-related surgery due to in-
sufficient response to medication or patient preference and 69 
patients (39.2%) developed AUR. 
  The patient demographics are shown in Table 1. The medica-
tion failure group was older than the medication maintenance 
group (66.4 vs. 62.2 years), but there were no significant differ-
ences in their medical disease history. Among the enrolled pa-
tients, 407 patients (60.1%) had received α-blocker monothera-
py and 270 patients (39.9%) had received combination medica-
tion (α-blocker and 5-ARI); the frequency of combination med-
ication was higher in the medication failure group. The medical 
treatment period was longer in the medication maintenance 
group (16.4 vs. 9.4 months).
  At baseline, the initial IPSS, prostate volume, transitional zone 
volume, and PVR were higher and the Qmax was lower in the 
medication failure group. The results of the logistic analysis for 
medication failure are shown in Table 2. Age, treatment type, 
and prostate volume were statistically significant factors associ-
ated with medication failure for BPH. 
  We analyzed clinical factors by prostate volume (less than 30 
g, n=231; 30 to 50 g, n=244; greater than 50 g, n=202) and by 
PSA level (less than 1.4 ng/mL, n=324; more than 1.4 ng/mL, 
n=353). The analysis by prostate volume is shown in Table 3. 
Age, PSA level, and cases of medication failure were higher and 
the medication period was shorter in patients with prostate vol-
umes over 30 g. The percentage of patients receiving combina-
tion treatment was higher among patients with prostate sizes of www.einj.or.kr    263
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more than 50 g than in the other groups. 
  Comparison of the variables stratified by PSA level with the 
cutoff of 1.4 ng/mL showed that age and the number of cases of 
medication failure, as well as prostate volume, were relatively 
high among patients with PSA levels greater than 1.4 ng/mL 
(Table 4). The paramount cutoff value for medication failure of 
prostate volume (area under the ROC curve, 0.68) was 34 g, 
with a sensitivity of 0.73 and a specificity of 0.52, and that of 
PSA (area under ROC curve 0.70) was 1.9 ng/mL, with a sensi-
tivity of 0.74 and a specificity of 0.58. The probability of cumu-
lative medication failure in patients with regard to a prostate 
volume of 34 g and a PSA level of 1.9 ng/mL are shown by Ka-
plan Meier plot in Fig. 1. 
DISCUSSION
BPH is a chronic, complex disease that is commonly associated 
with annoying symptoms of the lower urinary tract. Although 
Table 1.  Baseline clinical values of BPH patients: comparison 











Patients  161 516 0.02
 a)
Age (yr) 66.4±7.4
 a) 62.2±7.7 0.17
Medical disease cases 36 (22.7) 98 (18.9) 0.00
 a)






65 (40.4) 342 (66.3)
Combination therapy 96 (59.6)
 a) 174 (33.7)
Initial IPSS  21.8±6.5 16.4±7.1 0.01
 a)
BUN (mg/dL) 16.3±4.2 15.9±4.4 0.81
Creatinine (mg/dL) 1.1±0.3 1.0±0.2 0.51
PSA (ng/mL) 3.1±0.4 1.5±0.3 0.04
 a)
Qmax (mL/sec) 10.1±5.7 12.0±2.7
 a) 0.04
 a)
Residual vol (mL)  59.0±37.5
 a) 46.0±38.2 0.00
 a)
Prostate vol (g) 52.4±21.9
 a) 32.1±19.0 0.00
 a)
Values are presented as mean±SD or number (%).
BPH, benign prostatic hyperplasia; IPSS, International Prostate Symp-
tom Score; BUN, blood urea nitrogen; PSA, prostate-specific antigen; 
Qmax, maximum uroflow rate.
a) P-value<0.05.
















Odds ratio 1.030 0.937 0.968 0.987 1.026 0.979 0.971 1.032
95% CI 1.002-1.041 0.879-1.023 1.021-1.054 0.925-1.106 1.023-1.041 0.913-1.015 0.885-1.064 1.011-1.052
P-value 0.04
 a) 0.07 0.00
 a) 0.10 0.01
 a) 0.19 0.09 0.00
 a)
BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; PSA, prostate-specific antigen; Qmax, maximum uroflow rate; CI, 
confidence interval.
a) P-value<0.05.
Table 3.  Comparative study stratified by prostate volume in 
BPH patients
<30 g 30-50 g >50 g P-value
Patients   231 244 202










38 (40.4) 44 (66.3) 52 (66.3) 0.56
Medication period 
  (mo)





164 (71.0) 156 (63.9) 87 (43.1)
Combination 
  therapy
67 (29.0) 88 (36.1)  115 (56.9)
Initial IPSS 15.7±4.9 16.4±.3.9 17.8±.4.2 0.32
BUN (mg/dL) 15.1±0.4 17.3±0.3 16.2±0.3 0.51
Creatinine (mg/dL) 1.1±0.2 1.0±0.3 1.1±0.2 0. 64
PSA (ng/mL) 1.0±0.3 2.4±0.4 2.9±0.3 0.04
 a)
Qmax (mL/sec) 12.1±4.7 11.2±3.4 10.8±4.5 0.21
Residual vol (mL) 48.6±14.6  56.3±12.8  61.3±15.2 0.11
Values are presented as mean±SD or number (%).
BPH, benign prostatic hyperplasia; IPSS, International Prostate Symp-
tom Score; BUN, blood urea nitrogen; PSA, prostate-specific antigen; 
Qmax, maximum uroflow rate.
a) P-value<0.05.264    www.einj.or.kr
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medication provides an improvement in symptoms and uro-
flowmetric parameters in patients with BPH, the frequency of 
medical treatment failure and crossover to surgery remain un-
known. BPH can progress to cause severe complications such 
as AUR and BPH-related surgery [3]. In a survey conducted of 
men with BPH in five European countries, 58% and 56% of pa-
tients were ‘fairly’ and ‘very’ concerned about potential compli-
cations such as AUR and prostate-related surgery, respectively. 
Reducing the likelihood of requiring surgery was the most an-
ticipated treatment outcome. In other words, the risk for sur-
gery or AUR was a greater concern for patients than other fac-
tors such as symptom relief or quality of life [4,5].
  Although both surgery and medication treatment modalities 
are available for the management of BPH, transurethral pros-
tate surgery had been the most effective treatment for symp-
tomatic BPH. Recently, however, there has been agreement on 
the efficacy of medication treatment. 
  Treatment with α-blockers rapidly improves obstructive 
symptoms by relaxing the smooth muscles of the prostate and 
bladder neck, and 5-ARIs inhibit the conversion of testosterone 
to dihydro-testosterone within the prostate and decrease the 
prostate volume. α-Blockers can also induce apoptosis in the 
prostate glandular epithelium and stroma, by an unknown 
mechanism, but do not significantly reduce the cumulative in-
cidence of invasive therapy, and large studies have failed to show 
any effect of α-blockers on prostate volume. In one study, doxa-
zosin reduced the risk of symptomatic progression by 45% com-
pared with placebo and delayed the time to AUR. However, it 
did not considerably reduce the cumulative frequency of AUR 
at 4 years compared with placebo. In a survey of men treated 
Table 4.  Comparative study stratified by the PSA cut off level of 







Patients  324 353
Age (yr)  64.6±7.7 67.9±7.4 0.02
 a)
Medication failure cases 43 (17.6) 118 (27.3) 0.01
 a)
Medical disease 56 (22.9) 78 (18.1) 0.17




198 (61.1) 209 (59.2)
Combination therapy 126 (38.9) 144 (40.8)
Initial IPSS score 17.7±6.5  18.5±7.1 0.27
BUN (mg/dL) 16.3±4.2 15.9±4.4 0.81
Creatinine (mg/dL) 1.1±0.7 1.1±0.8 0.40
Qmax (mL/sec) 11.1±7.8 12.3±7.0 0.14
Residual vol (mL) 42.0±32.4 56.0±36.4 0.03
 a)
Prostate vol (g) 41.4±19.4 49.2±18.2 0.03
 a)
Values are presented as mean±SD or number (%).
PSA, prostate-specific antigen; BPH, benign prostatic hyperplasia; 
IPSS, International Prostate Symptom Score; BUN, blood urea nitro-
gen; Qmax, maximum uroflow rate.
a) P-value<0.05.
Fig. 1. Kaplan–Meier survival curve for the probability of cu-
mulative incidences of medication failure. Comparison was 
made by prostate volume (A) and PSA (B). (A) Probability of 
cumulative incidences of medication failure by prostate volume 
of 34 g. (B) Probability of cumulative incidence of medication 








  10.00  20.00  30.00  40.00
Prostate volume < 34 g










  10.00  20.00  30.00  40.00
PSA ≥ 1.9 ng/mL
PSA < 1.9 ng/mL
Bwww.einj.or.kr    265
  Choi, et al.  •  Medication Failure of BPH in Korea
doi: 10.5213/inj.2010.14.4.261
INJ
with finasteride, the relative risk of AUR was reduced by 57%, 
which was more than in men treated with a placebo (7%) [3,6]. 
Similarly, dutasteride studies have shown a reduced relative risk 
of AUR (57%) and surgical intervention (48%) compared with 
placebo at 2 years [7]. These effects could be explained by the 
prostate volume-reducing effects of 5-ARI. In another study, fi-
nasteride reduced prostate volume by 18% compared with a 14% 
increase with placebo [8]. 
  Current European Association of Urology guidelines for the 
management of BPH reflect this by stating that PSA, as a pa-
rameter for prostate volume, can be used to evaluate the risks of 
either requiring surgery or developing AUR [9]. Serum PSA is 
easily measured in clinical practice and can therefore facilitate 
the identification of those men with BPH at risk for disease pro-
gression and help to guide therapeutic decisions. Although the 
precise relationship between PSA and prostate growth may vary 
from one individual to another, analysis of the data showed that 
PSA thresholds for detecting a prostate volume ≥30 g were 
≥1.3 ng⁄mL, ≥1.5 ng⁄mL, and ≥1.7 ng⁄mL in men with BPH in 
the 50 to 59-, 60 to 69-, and 70 to 79-year-old age groups [10].
  Many studies have focused on the PSA threshold levels of 1.4 
or 2.0 ng⁄mL to identify patients at high risk for BPH progres-
sion. Our study also showed differences in age, the medication 
treatment failure rate, and prostate size according to the cutoff 
of 1.4 ng⁄mL. However, the treatment pattern with regard to the 
frequency of combination therapy was not significantly differ-
ent between the two groups. Therefore, there were discrepan-
cies with the updated current protocols. Finasteride in combi-
nation with terazosin, doxazosin, or alfuzosin failed to show a 
benefit in the patients receiving combination therapy over pla-
cebo or alpha-blocker monotherapy in terms of improving the 
Qmax; in addition, in this study it did not show a correlation 
with medication failure [11]. 
  Prostate volume is perhaps the most extensively studied of 
the risk factors for BPH progression. Men with a prostate vol-
ume of ≥30 g are more likely to have moderate-to-severe symp-
toms (3.5-fold increase), decreased flow rates (2.5-fold increase), 
and AUR (three- to fourfold increase) than are men with a pros-
tate volume <30 g [8]. Jacobsen et al. [12] reported that if the 
prostate volume was larger than 30 g, the incidence of AUR was 
increased at least threefold. In clinical practice, however, the 
volume guidelines for combination medication were vague and 
between 30 g and 50 g. We analyzed prostate volume and treat-
ment protocol. There was a relatively high frequency of patients 
in the medical failure group among men with a prostate volume 
of more than 30 g. However, the frequency of combination treat-
ment was higher only in men with a prostate volume of more 
than 50 g. Therefore, the men with prostate volumes in the 30 g 
to 50 g range received a relatively lower rate of combination 
therapy, but had a similar rate of medication failure. Because 
adverse effects (erectile dysfunction, ejaculatory disorders, and 
decreased libido) are more common with combination therapy 
than with monotherapy, patients and/or treating physicians 
hesitate to use 5-ARI combination treatment. Korean people 
are more afraid of the side effects related to these sexual prob-
lems, and our results are a reflection of such inclinations. On 
the other hand, several studies have reported low levels of con-
fidence with 5-ARI for the treatment of BPH. For example, 
Lepor et al. [13] concluded that finasteride alone or in combi-
nation with terazosin was no more effective than placebo or 
terazosin alone. The reason for the high rate of combination 
treatment in the medication failure group is that these patients 
usually include those who were candidates for BPH-related sur-
gery due to their high prostate volumes. However, many pa-
tients with intermediately enlarged prostates might not be treat-
ed with combination therapy, even though they have a high rate 
of medication failure. 
  Choosing the patients who will benefit from medication and 
determining the most effective course of treatment continue to 
be topics of study. Patients should be presented with a reason-
able estimate of their baseline risk of disease progression along 
with the risks and benefits of medication therapy and the need 
for combination medication so that a proper decision can be 
made. The results of the present study showed that the frequen-
cy of AUR and BPH-related surgery was significantly higher in 
patients receiving 5-ARI combination therapy because of their 
high prostate volumes. Prostate volume appeared to be the most 
significant associated factor; it was related to both age and the 
PSA level. However, it cannot be used alone as an independent 
factor to guide BPH treatment options. Other parameters such 
as the symptom score, PVR, or Q-max must also be considered. 
All treatments resulted in a significant improvement in the symp-
tom scores, with combination therapy superior to α-blocker 
monotherapy [8]. Worsening of the PVR has been shown to be 
a good predictor of AUR in men with LUTS suggestive of BPH 
[14]. 
  Derived from the ROC curve, cutoff values of prostate vol-
ume and PSA for predicting medical treatment failure were 34 
g and 1.9 ng⁄mL, respectively. We suggest that these cutoffs of 
prostate volume and PSA can be used in combination to coun-266    www.einj.or.kr
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sel patients at their initial visit. Although our study was a retro-
spective study and included a limited number of cases, it has 
revealed the proper cutoffs for prostate volume and serum PSA 
level for combination treatment to be effective. Studies on the 
benefits of long-term combination treatment are needed, espe-
cially in patients with an intermediate increase in prostate and 
PSA levels.
  In conclusion, age, medication treatment period, treatment 
type, and prostate volume were found to be risk factors for fu-
ture surgery or AUR. Patients with a prostate volume of more 
than 30 g were more likely to be in the medication failure group. 
Combination treatment was relatively low for the patients with 
prostate volumes of less than 50 g. Based on a PSA cutoff of 1.4 
ng⁄mL, age, the medication failure rate, and prostate size differed, 
but the rate of combination therapy did not. Therefore, patients 
with a prostate volume of 30 g to 50 g and a PSA over 1.4 ng⁄mL 
should be considered for combination therapy more often to 
prevent medication failure in Korea. Additionally, our sugges-
tive cutoff values are a prostate volume of 34 g and a PSA level 
over 1.9 ng/mL. 
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